Last update May 20, 2024
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Diazoxide in other languages or writings:
Diazoxide belongs to these groups or families:
Variable | Value | Unit |
---|---|---|
Molecular weight | 231 | daltons |
Protein Binding | 90 | % |
pKa | 8.74 | - |
Tmax | 0.1 | hours |
T½ | 28 ± 8.3 | hours |
Theoretical Dose | 0.11 - 0.46 | mg/Kg/d |
Relative Dose | 3.6 - 15.9 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A drug with hyperglycemic and antihypertensive action via peripheral vasodilatation. Indicated orally (2 to 3 daily doses) in the treatment of unresponsive hyperglycemia by hyperinsulinism and intravenously in hypertensive crises. Its use is authorized in the neonatal and infant period.
It is excreted in breast milk in small amounts, but could be clinically significant. (Saito 2022)
A newborn partially breastfed by a mother taking diazoxide orally had no clinical problems or alterations in blood glucose at one month of life. (Saito 2022)
If Diazoxide is taken during lactation, it is advisable to monitor the infant's blood glucose regularly.
Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable (Schaefer 2015 p790), especially during the neonatal period and in case of prematurity.